Please assess the completion status of the following clinical trial:

Trial Title: Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥ 18 years~* Symptomatic and chronic heart failure (NYHA Class II and III).~* Patients on guideline directed medical therapy 90 days prior to enrollment.~* Adequate home environment for at-home treatment.~* Presenting or referred to the clinic because of evidence of worsening heart failure with fluid overload (decompensation).~* A modification in oral diuretics is not clinically appropriate as deemed by the investigator.~* Estimated excess fluid weight of 4 lbs. or more from euvolemic state.~* Participant able to give informed consent for participation in trial. Agreeing to sign informed consent and HIPAA authorization.~* Understanding and willing to comply with the protocols of the trial.~* Ability of the participant or caregiver to independently apply the investigational device and medication~Exclusion Criteria:~* ACC/AHA Stage D heart failure or patients requiring IV inotrope therapy.~* Massive volume overload (e.g. \>20 lbs. of estimated fluid weight) or anasarca.~* Suspected high risk clinical instability with outpatient treatment.~* Pregnant females or women of child-bearing age who are not willing to use an adequate form of contraception.~* Chronic Obstructive Pulmonary Disease (COPD) moderate or worse: FEV1/FCV ratio \<0.7 and FEV1 \<60 percent predicted.~* Rapid atrial fibrillation (AF) (HR \>100b/min)~* Hypoxia (resting O2 saturation \<90%).~* Hypotension (systolic blood pressure (SBP) BP \< 90 mmHg).~* Uncontrolled diabetes mellitus (DM) (admission glucose levels \> 300 mg/dL).~* Advanced renal disease (eGFR \< 30mL/min/1.73m2).~* Acute coronary syndrome.~* Serum potassium (K) \<3.2 mmol/L or \> 5.5mmol/L.~* On experimental medication or currently participating in an interventional cardiovascular research study, other than an observational or registry study.~* Having received intravenous furosemide within 24 hours prior to enrollment.~* Urinary tract abnormality or disorder interfering with urination.~* Allergy to the active and inactive ingredients of the study medication.~* Inability to comply with study requirements.~* Ongoing substance abuse.~* Concern that the current episode of decompensation was precipitated by a serious medical condition which may require additional evaluation or treatment.~* Dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- In-Home Subcutaneous Furosemide Treatment ARm (Type: EXPERIMENTAL): Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).